Tamera Jones | 21 May 2010 | Planet Earth Online
Malaria parasites that are sensitive to anti-malarial drugs could evolve to cause more serious illness in people who don't get treated with drugs, researchers have discovered. Scientists found that stressing drug-sensitive Plasmodium falciparum
parasites by exposing them to low levels of anti-malarial drugs makes
them change their behaviour.
Josephine Katabaazi Nakyanzi et al | 12 Feb 2010 | World Health Organization
The expiry of medicines in the supply chain is a serious threat to the already constrained access to medicines in developing countries. We investigated the extent of, and the main contributing factors to,
expiry of medicines in medicine supply outlets in Kampala and Entebbe,
Edith Patouillard et al | 11 Feb 2010 | Malaria Journal
In many low-income countries, the retail sector plays an important role in the treatment of malaria and is increasingly being considered as a channel for improving medicine availability.
Quique Bassat et al | 17 Nov 2009 | PLoS One
Artemisinin combination therapies (ACTs) are currently the preferred option for treating uncomplicated malaria. Dihydroartemisinin-piperaquine (DHA-PQP) is a promising fixed-dose ACT with limited information on its safety and efficacy in African children.
Jane Chuma et al | 28 Oct 2009 | Malaria Journal
Effective case management is central to reducing malaria mortality and morbidity worldwide, but only a minority of those affected by malaria, have access to prompt effective treatment.
Karen Barnes, Pascalina Chanda & Gebre Ab Barnabas | 12 Oct 2009 | Malaria Journal
Malaria is one of the most significant causes of morbidity and mortality worldwide. Every year, nearly one million deaths result from malaria infection.
Jean-Robert Ioset et al | 30 Sep 2009 | PLoS One
Malaria continues to be one of the major public health problems in Africa, Asia and Latin America. Artemisinin derivatives (ARTs; artesunate, artemether, and dihydroartemisinin) derived from the herb, Artemisia annua, are the most effective antimalarial drugs available providing rapid cures.
Julien Zwang et al | 23 Aug 2009 | Malaria Journal
Artesunate and amodiaquine (AS&AQ) is at present the world's second most widely used artemisinin-based combination therapies (ACT). Evaluating the efficacy of ACT recently adopted by the World Health Organisation (WHO) and deployed over 80 countries was necessary to make evidence base drug policy.
None | 29 Jul 2009 | Africa Fighting Malaria
For decades, Nigeria has been plagued by counterfeit and poor-quality medicines, yet little information exists on the extent to which healthcare personnel are aware of counterfeit and substandard medicines, and how this influences their behavior.
Suerie Moon et al | 21 Jul 2009 | PloS Medicine
Almost 40 years ago, Chinese scientists rediscovered the near-miraculous potency of artemisinin derivatives against malaria. Today, we are approaching a decade since the WHO recommended that ACTs replace older antimalarials rendered ineffective by resistance.